| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.057 | 0.08 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.059 | 0.08 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | 0.083 | 0.08 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.31 | 0.08 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.08 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.052 | 0.09 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.09 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.09 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.083 | 0.09 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.09 |